钟志远特聘教授
国际创新药学院院长、药学院院长
国家杰出青年基金获得者
全球高被引科学家、美国医学与生物工程院会士
Journal of Controlled Release (IF 10.8)副主编
E-mail：zyzhong@suda.edu.cn
个人简介
钟志远特聘教授，国际创新药学院院长，药学院院长，放射医学与辐射防护国家重点实验室靶向放药中心主任、国家生物药技术创新中心苏州大学分中心负责人。主要从事药物控制释放、肿瘤靶向治疗和免疫治疗研究。在国际主流期刊发表论文320篇，引用2.5万多次，H-因子83。授权60多项国家和国际发明专利（转让12项）。现主持1项国家基金委重点项目和1项国家重点研发计划项目课题。入选国家杰出青年基金获得者，国家“万人计划”创新领军人才，国家百千万工程人才，美国医学与生物工程院会士。自2014年起连续10年入选中国高被引学者，2018年起连续6年入选全球高被引科学家。享受国务院政府特殊津贴。担任药学TOP期刊Journal of Controlled Release（IF 10.8)邀稿和综述主编。担任Materials Today、Biomacromolecules、ACS Biomaterials Science & Engineering、Materials Today Chemistry、PLoS One等8本国际期刊编委。曾任Biomacromolecules副主编和苏州BioBAY副总裁。荣获美国化学会“生物大分子/大分子青年研究者奖”、德国洪堡基金会“贝塞尔研究奖” 、日本控制释放学会 “亚洲药物释放系统突破技术奖”等国际奖励。
研究方向
1. 智能囊泡药物用于肿瘤和免疫性疾病等的靶向治疗
2. 脑靶向递送系统与重大脑疾病治疗
3. 核酸药物靶向递送与基因治疗
4. 靶向放射性药物创新与转化
5. 蛋白药物定点递送与肿瘤免疫治疗
代表性论文（*代表通讯作者）
1. S.J. Yue, J.N. An, Y.F. Zhang, J.Y. Li, C.Z. Zhao, J.Y. Liu, L.L. Liang, H.L. Sun*, Y. Xu*, Z.Y. Zhong*, Exogenous Antigen Upregulation Empowers Antibody Targeted Nanochemotherapy of Leukemia, Adv. Mater. 2023, 2209984.
2. J.W. Du, S.J. Yue, C.M. Li, J.Y. Li, S.S. Zhao, Y.Y. Dong, Y.F. Zhang, R. Cheng, H.L. Sun*, Z.Y. Zhong*, Exogenous CD38 upregulation enables high-efficacy dually cascade targeted molecular therapy of leukemia, Nano Today 2023, 50, 101872.
3. W.C. Yan, B.B. Guo, Z. Wang a, J.T. Yang, Z.Y. Zhong*, F.H. Meng*, RGD-directed 24 nm micellar docetaxel enables elevated tumor-liver ratio, deep tumor penetration and potent suppression of solid tumors, J. Control. Release 2023, 360, 304-315.
4. Y.J. Li, X.Y. Li, J.M. Yi, Y.J. Cao, Z.H. Qin*, Z.Y. Zhong*, W.J. Yang*, Nanoparticle-Mediated STING Activation for Cancer Immunotherapy, Adv. Healthc. Mater. 2023, 2300260
5. M.Y. He, M.Y. Wang, T. Xu, M.Y. Zhang, H.X. Dai, C. Wang*, D.W. Ding*, Z.Y. Zhong*, Reactive oxygen species-powered cancer immunotherapy: Current status and challenges, J. Control. Release 2023, 356, 623-648.
6. J.G. Xie, X.F. Zhao, P. Zhang, Y.Y. Zhang, R. Cheng, Z.Y. Zhong*, C. Deng*, Codelivery of BCL2 and MCL1 Inhibitors Enabled by Phenylboronic Acid-Functionalized Polypeptide Nanovehicles for Synergetic and Potent Therapy of Acute Myeloid Leukemia, Adv. Sci. 2023, 10, 2204866.
7. B.B. Guo, Y. Qu, Y.P. Sun, S.S. Zhao, J.D. Yuan, P.Z. Zhang, Z.Y. Zhong*, F.H. Meng*, Co-delivery of gemcitabine and paclitaxel plus NanoCpG empowers chemoimmunotherapy of postoperative cold triple-negative breast cancer, Bioactive Mater. 2023, 25, 61-72.
8. Y.P Sun, Y.J.Sha, G.H. Cui, F.H. Meng*, Z.Y. Zhong*, Lysosomal-mediated drug release and activation for cancer therapy and immunotherapy, Adv. Drug Deliv. Rev. 2023, 192, 114624.
9. Y.F. Xia, J.N. An, J.Y. Li, W.X. Gu, Y.F. Zhang, S.S. Zhao, C.Z. Zhao, Y. Xu, B. Li, Z.Y. Zhong*, F.H. Meng*, Transferrin-guided intelligent nanovesicles augment the targetability and potency of clinical PLK1 inhibitor to acute myeloid leukemia, Bioactive Mater. 2023, 21, 499-510.
10. J. Sun, Z.Y. Huangfu, J.T. Yang, G.L. Wang*, K. Hu*, M.Y. Gao, Z.Y. Zhong*, Imaging-Guided Targeted Radionuclide Tumor Therapy: From Concept to Clinical Translation, Adv. Drug Deliv. Rev. 2022, 190, 114538.
11. X.Y.Ji*, Z.Y. Zhong*, External stimuli-responsive gasotransmitter prodrugs: Chemistry and spatiotemporal release, J. Control. Release 2022, 351, 81-101.
12. J.J. Jiang, R.X. Wang, L. Yang, Y.J. Sha, S.S. Zhao, D.F. Chen*, Z.Y. Zhong*, F.H. Meng*, IL-11Rα-targeted nanostrategy empowers chemotherapy of relapsed and patient-derived osteosarcoma, J. Control. Release 2022, 350, 460-470.
13. J.Y. Liu, L. Zhang, D.X. Zhao, S.J. Yue, H.L. Sun*, C.F. Ni*, Z.Y. Zhong*, Polymersome-stabilized doxorubicin-lipiodol emulsions for high-efficacy chemoembolization therapy, J. Control. Release 2022, 350, 122-131.
14. H. Zheng, B.B. Guo, X.Y. Qiu, Y.F. Xia, Y. Qu, L. Cheng*, F.H. Meng*, Z.Y. Zhong*, Polymersome-Mediated Cytosolic Delivery of Cyclic Dinucleotide STING Agonist Enhances Tumor Immunotherapy, Bioactive Mater. 2022, 16, 1-11.
15. Y. Zheng*, Z.Y. Zhong*, Roadmap to next-generation cancer vaccines, J. Control. Release 2022, 347, 308-313.
16. J.J. Wei, D. Wu, Y. Shao, B.B. Guo, J.J. Jiang, J. Chen, J.P. Zhang, F.H. Meng*, Z.Y. Zhong*, ApoE-mediated systemic nanodelivery of granzyme B and CpG for enhanced glioma immunotherapy, J. Control. Release 2022, 347, 68-77.
17. J.J. Wei, D. Wu, S.S. Zhao, Y. Shao, Y.F. Xia, F.H. Meng*, D.W. Ni, X.Y. Qiu, J.P. Zhang, J. Chen*, and Z.Y. Zhong*, Immunotherapy of Malignant Glioma by Non-Invasive Administration of TLR9 Agonist CpG Nano-immunoadjuvant, Adv. Sci. 2022, 9, 2103689.
18. H.H. Fang, Y.J. Sha, L. Yang, J.J. Jiang, L.C. Yin, J.Y. Li, B. Li, B. Klumperman, Z.Y. Zhong*, and F.H. Meng*, Macrophage-Targeted Hydroxychloroquine Nanotherapeutics for Rheumatoid Arthritis Therapy, ACS Appl. Mater. Interfaces 2022, 14, 8824-8837.
19. X.Y.Qiu, Y.Qu, B.B.Guo, H.Zheng, F.H. Meng*, and Z.Y. Zhong*, Micellar paclitaxel boosts ICD and chemo-immunotherapy of metastatic triple negative breast cancer, J. Control. Release 2022, 341, 498-510.
20. Y.F. Zhang, S.J. Yue, H.L. Sun*, R. Haag, Z.Y. Zhong*, An intelligent cell-selective polymersome-DM1 nanotoxin toward triple negative breast cancer, J. Control. Release 2021, 340, 331-341.
21. Z. Wang, F.H. Meng, and Z.Y. Zhong*, Emerging targeted drug delivery strategies toward ovarian cancer, Adv. Drug Deliv. Rev. 2021, 178, 113969
22. N. Yu, Y.F. Zhang, J.Y. Li, W.X. Gu, S.J. Yue, B. Li, F.H. Meng, H.L. Sun*, R. Haag, J.D. Yuan, and Z.Y. Zhong*, Daratumumab Immunopolymersome-Enabled Safe and CD38-Targeted Chemotherapy and Depletion of Multiple Myeloma, Adv. Mater. 2021, 33, 2007787.
23. Y.H. Wei, Y.P. Sun, J.J. Wei, X.Y. Qiu, F.H. Meng*, G. Storm*, J.D. Yuan, Z.Y. Zhong*, Selective transferrin coating as a facile strategy to fabricate BBB-permeable and targeted vesicles for potent RNAi therapy of brain metastatic breast cancer in vivo, J. Control. Release 2021, 337, 521-529.
24. W.X. Gu, R.B. Qu, F.H. Meng*,J.L.M. Cornelissen*, and Z.Y. Zhong*, Polymeric Nanomedicines Targeting Hematological Malignancies, J. Control. Release 2021, 337, 571-588.
25. Y.F. Xia, J.J. Wei, S.S. Zhao, B.B. Guo, F.H. Meng*, B. Klumperman, and Z.Y. Zhong*, Systemic administration of polymersomal oncolytic peptide LTX-315 combining with CpG adjuvant and anti-PD-1 antibody boosts immunotherapy of melanoma, J. Control. Release 2021, 336, 262-273.
26. Q.Y. Fan, Y.Y. Liu, G.H. Cui, Z.Y. Zhong*, and C. Deng*, Brain delivery of Plk1 inhibitor via chimaeric polypeptide polymersomes for safe and superb treatment of orthotopic glioblastoma, J. Control. Release 2021, 329, 1139-1149.
27. W.X. Gu, T.H. Liu, D.Y. Fan, J.B. Zhang, Y.F. Xia, F.H. Meng*, Y. Xu*, J.L.M. Cornelissen, Z.J. Liu, and Z.Y. Zhong*, A6 peptide-tagged, ultra-small and reduction-sensitive polymersomal vincristine sulfate as a smart and specific treatment for CD44+ acute myeloid leukemia, J. Control. Release 2021, 329, 706-716.
28. W.X. Gu, F.H. Meng*, R. Haag, and Z.Y. Zhong*, Actively targeted nanomedicines for precision cancer therapy: Concept, construction, challenges and clinical translation, J. Control. Release 2021, 329, 676-695.
29. C. Gao, Q. Cheng, J.W. Wei, C. Sun, S.Y. Lu, C.H.T. Kwong, S.M.Y. Lee, Z.Y. Zhong*, and R.B. Wang*, Bioorthogonal supramolecular cell-conjugation for targeted hitchhiking drug delivery, Mater. Today 2020, 40, 9-17.
30. C. Deng*, Q. Zhang, J.Q. Guo, X.F. Zhao, and Z.Y. Zhong*, Robust and smart polypeptide-based nanomedicines for targeted tumor therapy, Adv. Drug Deliv. Rev. 2020, 160, 199-211.
31. Y.H. Wei, F.H. Meng*, G. Storm, and Z.Y. Zhong*, Transferrin-Binding Peptide Functionalized Polymersomes Mediate Targeted Doxorubicin Delivery to Colorectal Cancer In Vivo, J. Control. Release 2020, 319, 407-415.
32. Y.N. Zhong, F.H. Meng*, W. Zhang, B. Li, J. van Hest, and Z.Y. Zhong*, CD44-Targeted Vesicles Encapsulating Granzyme B as Artificial Killer Cells for Potent Inhibition of Human Multiple Myeloma in Mice, J. Control. Release 2020, 320, 421-430.